Quess Corp, India’s leading business services provider, announced the launch of its new healthcare vertical to address the shortage of healthcare professionals.
The vertical aims to provide trained healthcare manpower, home care solutions, and end-to-end hospital management services by identifying, training & upskilling healthcare professionals through a network of accredited medical training institutes, enabling quick & on-demand deployment.
Quess Corp has signed an MoU with the Association of Healthcare Providers (India) (AHPI), a not-for-profit representative body of healthcare providers, to evangelize formalization of training and staffing services for healthcare professionals and create a talent marketplace for private and public healthcare institutions.
The collaboration aspires to create a pipeline of trained paramedical and healthcare service professionals through a proposed hire-train-deploy model, besides building a digital pool of highly skilled, experienced, ready-to-hire doctors across India.
In addition to creating an organized demand and supply support service for healthcare manpower such as nurses, paramedics, doctors, phlebotomists, and lab technicians, the collaboration will also enable corporates to set up safer workspaces with adequate medical facilities, and to train candidates with endorsements from reputed domestic and international accreditations. Through this alliance, Quess Corp and AHPI plan to jointly work towards industry advocacy in critical areas of staffing and healthcare manpower management.
Dr Naresh Shetty, president, Quess Healthcare said, “In India, the healthcare segment faces dismaying challenges with an acute shortage of skilled manpower to the tune of six million paramedics today. We hope to bridge this gap and indisputably impact skill development and knowledge enhancement of the healthcare sector, which is the absolute need of the hour. Through tech-enabled skilling and access to a talent pool of trained professionals, we want to empower healthcare providers to cater to a wide public reach while providing access to quality healthcare for all.”
Dr Giridhar Gyani, director general, AHPI said “Improving the Indian healthcare system by expanding basic healthcare access to the larger community has been our long-standing commitment at AHPI. We are pleased to partner with Quess Corporation, the leading manpower service company, and believe that together, we can successfully redesign and advocate for the medical ecosystem with trained and qualified workforce.”
Donald Trump’s tariffs of 50% have come into force on most US imports from India. India’s giant generic pharmaceuticals sector and its electronics and petroleum products are exempt from the tariffs. Aluminium, steel and copper remain at 25%, but job-heavy sectors such as textiles, jewellery, seafood and leather are squarely in the line of fire.
The European Chemicals Agency (ECHA) has published the updated proposal to restrict per- and polyfluoroalkyl substances (PFAS) under the EU’s chemicals regulation, REACH. The update has been prepared by the authorities from Denmark, Germany, the Netherlands, Norway and Sweden, who submitted the initial proposal in January 2023.
Most chemicals exported from the 27 member countries of the European Union into the US will be subject to a 15% tariff on top of their selling prices under an agreement signed on July 27 between the US and the European Commission.
We’re thrilled to announce a new strategic alliance between ExSyn, Exim-Indis and simABs, a leading EU-based biologics manufacturer known for its patented continuous flow technology in antibody production.
The global trade landscape is undergoing significant changes following the announcement of new reciprocal tariffs by the United States government. Recent developments indicate significant shifts in global trade dynamics, with key policy adjustments, ongoing negotiations, and evolving logistics patterns. Below is a summary of the latest developments.
In January 2025, the US FDA published a draft regulatory guidance entitled “The Considerations for Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products”.
The adoption of artificial intelligence (AI) and large language models (LLMs) is rapidly reshaping clinical research and drug development.
In the quest for increased sustainability, a lot has been made of the potential to use bio-based raw materials, captured CO2 and recycled plastics as raw materials for new chemicals. But what about using biotech processes to manufacture chemicals? Could it offer a more sustainable alternative to traditional petrochemical processing, and be more amenable to biobased raw materials?
High duties on imports from Canada, Mexico and China raise problems for international supply chains.